On Friday, February 28, Drs. and Rekhtman of Memorial Sloan Kettering Cancer Center joined us on Facebook Live to discuss the role of pathologists in SCLC, why the right diagnosis is key, and the logistics and importance of biopsies. They explained forms of SCLC such as atypical, transformed, and RB proficient. Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in small cell lung cancer (SCLC).

Mya Tran, PharmD, BCOP, joined us in January to discuss what people should expect during treatment for small cell lung cancer (SCLC), managing side effects related to SCLC therapy, as well as the importance of genomics and its role in molecularly informed clinical trials for SCLC. Moderated by Dr. Misty Shields, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in SCLC.

Read time: 2 minutes. Researchers have been trying to find new ways to treat small cell lung cancer (SCLC) for a long time. Those efforts are starting to pay off in big ways. Join Stephen Liu, MD, of Georgetown Lombardi Comprehensive Cancer Center, and Amy Moore, PhD, of LUNGevity Foundation, as they walk us through the treatment options for SCLC, including exciting breakthroughs on the horizon. This video was part of LUNGevity’s International Lung Cancer Survivorship Conference (ILCSC)—a free, virtual conference for people with lung cancer and their loved ones—in September 2024. Since

Read time: 2 minutes. Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can watch the entire video, or use the timestamps below. Make sure to watch parts 1 and 2 of this series here: How Can

Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients and Researchers Design Clinical Trials Together, you can watch it here. Watch Part 2 below, or use the timestamps to skip to a

Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here. 2024 ASCO: Highlights of Lung Cancer Research In June, we recapped the annual American Society of Clinical Oncology meeting. Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates

Triparna Sen, PhD, Icahn School of Medicine at Mount Sinai, New York, joined us for our September Small Cell SMASHERS Facebook Live event. Dr. Sen discussed the biology and the role of biomarkers in small cell lung cancer. Moderated by Dr. Misty Shields, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in small cell lung cancer (SCLC).

Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. You can read the other update blogs from these fall science meetings: Metastatic NSCLC Highlights Small Cell Lung Cancer Highlights Early-Stage and Locally Advanced NSCLC Cancer screening involves tests that can detect early-stage cancer when

Missed the Facebook Live? Watch the video! On Tuesday, October 8, Christine Lovly, MD, PhD, discussed the importance of clinical trials and the role of translational research in small cell lung cancer (SCLC). The discussion was moderated by Misty Shields, MD, IU Health, and LUNGevity’s Amy C. Moore, PhD and VP of Global Engagement and Research Partnerships. This monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug Development? Part 2: How We Define Success for a Clinical Trial The United States federal government aims to regulate prescription drugs to ensure people are receiving medication that’s safe and effective. Every prescribed drug in the U.S. has gone through a rigorous testing process that can take over a decade to complete before the U.S. Food and Drug Administration (FDA) approves the drug and people can benefit from